Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Preclinical Development: Overview01:28

Preclinical Development: Overview

5.6K
Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...
5.6K
Drug Discovery: Overview01:26

Drug Discovery: Overview

10.7K
Drug discovery is a multifaceted process involving extensive screening, testing, and optimization of lead compounds to identify potential new drugs for therapeutic use. It combines several approaches, including screening large numbers of natural products, chemical modification of known active molecules, identification of new drug targets, and rational design based on biological mechanisms and drug-receptor structure. These approaches are carried out in both academic research laboratories and...
10.7K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Serum Proteomic Profiling Implicates a Dysregulated Neurohormonal-Inflammatory Axis in Post-Fontan Sinus Tachycardia.

Journal of the American Heart Association·2026
Same author

Genome-wide mapping of DNA G-quadruplexes in Trypanosoma brucei chromatin reveals enrichment in coding regions and transcription start sites.

Nucleic acids research·2026
Same author

Synthesis and Evaluation of Nitroheterocyclic Aromatic Adamantanohydrazones with Trypanocidal Activity. Part III.

ACS infectious diseases·2026
Same author

Rational design of novel organometallic <i>N</i>-acylhydrazones with potent antiparasitic activity on <i>Trypanosoma cruzi</i> and <i>brucei</i>.

Dalton transactions (Cambridge, England : 2003)·2026
Same author

Feasibility of Magnetic Resonance Imaging-Guided Pulmonary Artery Stenting in a Commercial Wide-Bore 0.55-T Scanner.

JACC. Basic to translational science·2026
Same author

Overcoming Trypanosoma cruzi persistence with a mechanistically distinct drug combination.

npj antimicrobials and resistance·2026

Related Experiment Video

Updated: Dec 17, 2025

In Vitro Drug Screening Against All Life Cycle Stages of Trypanosoma cruzi Using Parasites Expressing &#946;-galactosidase
08:48

In Vitro Drug Screening Against All Life Cycle Stages of Trypanosoma cruzi Using Parasites Expressing β-galactosidase

Published on: November 5, 2021

3.6K

Challenges in Chagas Disease Drug Development.

Amanda F Francisco1, Shiromani Jayawardhana1, Francisco Olmo1

  • 1Department of Infection Biology, London School of Hygiene and Tropical Medicine Keppel Street, London WC1E 7HT, UK.

Molecules (Basel, Switzerland)
|June 21, 2020
PubMed
Summary

Developing new treatments for Chagas disease (caused by *Trypanosoma cruzi*) is crucial due to limited current options. Recent systematic research and collaborations offer a more optimistic outlook for effective drug development.

Keywords:
Chagas diseaseTrypanosoma cruzidrug development

More Related Videos

Author Spotlight: Real-Time Monitoring of Parasite Burden and Host Response
07:59

Author Spotlight: Real-Time Monitoring of Parasite Burden and Host Response

Published on: May 31, 2024

1.9K
Introducing a Gene Knockout Directly Into the Amastigote Stage of Trypanosoma cruzi Using the CRISPR/Cas9 System
06:13

Introducing a Gene Knockout Directly Into the Amastigote Stage of Trypanosoma cruzi Using the CRISPR/Cas9 System

Published on: July 31, 2019

9.4K

Related Experiment Videos

Last Updated: Dec 17, 2025

In Vitro Drug Screening Against All Life Cycle Stages of Trypanosoma cruzi Using Parasites Expressing &#946;-galactosidase
08:48

In Vitro Drug Screening Against All Life Cycle Stages of Trypanosoma cruzi Using Parasites Expressing β-galactosidase

Published on: November 5, 2021

3.6K
Author Spotlight: Real-Time Monitoring of Parasite Burden and Host Response
07:59

Author Spotlight: Real-Time Monitoring of Parasite Burden and Host Response

Published on: May 31, 2024

1.9K
Introducing a Gene Knockout Directly Into the Amastigote Stage of Trypanosoma cruzi Using the CRISPR/Cas9 System
06:13

Introducing a Gene Knockout Directly Into the Amastigote Stage of Trypanosoma cruzi Using the CRISPR/Cas9 System

Published on: July 31, 2019

9.4K

Area of Science:

  • *Trypanosoma cruzi* infection
  • Chagas disease pathogenesis
  • Antiparasitic drug discovery

Background:

  • Chagas disease, caused by *Trypanosoma cruzi*, is a significant public health issue in Latin America.
  • Current treatments for Chagas disease exhibit limited efficacy, prolonged treatment durations, and considerable toxicity.
  • Progress in Chagas disease therapeutics has been hindered by incomplete understanding of disease mechanisms, parasite biology, and drug actions.

Purpose of the Study:

  • To provide an overview of the current landscape of drug development for Chagas disease.
  • To identify promising areas for future advancements in Chagas disease therapeutics.
  • To illustrate the role of fundamental research in supporting drug development for Chagas disease.

Main Methods:

  • Systematic drug-based research initiatives.
  • Collaborations between academic institutions and commercial entities.
  • High-throughput screening of compound libraries.
  • Drug repurposing strategies.
  • Optimization of existing treatment regimens.
  • Leveraging laboratory research findings.

Main Results:

  • Increased systematic approach to drug research for Chagas disease.
  • Enhanced collaborations fostering drug development efforts.
  • Application of high-throughput screening and technological advancements.
  • Integration of drug repurposing and regimen optimization.
  • Foundation for new clinical trials based on research.

Conclusions:

  • Despite challenges, the Chagas disease drug development landscape is becoming more optimistic.
  • Systematic research, collaborations, and technological advancements are accelerating progress.
  • Fundamental research plays a vital role in underpinning and guiding the development of new Chagas disease therapies.